Home

ROBERT E CONWAY

CIK 1184334 · CEO · last filed 2024-05-20

ROBERT E CONWAY is a CEO who has filed 52 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for ALPN, was dated May 20, 2024. Across all open-market trades the lifetime net is +$954.9K, making them a net buyer over the disclosed history. 24 SEC filings were submitted jointly with ARRAY BIOPHARMA INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

52

Lifetime Open-Market Net

$954.9K

Filer Profile

Reported Address
C/O ARCA BIOPHARMA, INC
8001 ARISTA PLACE, STE 430
BROOMFIELD, CO 80021
Formerly Known As
CONWAY ROBERT (2003–2011)
Related Filers
ARRAY BIOPHARMA INC — 24 joint filings, latest 2011-10-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Director 0 $64.97 $0 $480.6K 12 2024-05-20
Oruka Therapeutics, Inc. (ABIO) Delisted Director 4,167 $28.80 $120.0K $278.9K 17 2024-01-31
ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted Director 15,000 — — $195.5K 8 2017-05-11

Recent Filings

52 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-05-20 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Disp (D) −50,000 $0 EDGAR
2024-01-31 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2024-01-04 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) — $0 EDGAR
2023-01-05 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) — $0 EDGAR
2022-12-19 Oruka Therapeutics, Inc. (ABIO) Delisted Grant (A) — $0 EDGAR
2022-01-04 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) — $0 EDGAR
2021-09-27 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Buy (P) +15,000 $151.2K EDGAR
2021-09-24 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Sell (S) +15,000 $151.2K EDGAR
2021-09-23 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Buy (P) +10,000 $98.0K EDGAR
2021-05-13 Oruka Therapeutics, Inc. (ABIO) Delisted Buy (P) +10,000 $31.9K EDGAR
Showing 1–10 of 52
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.